Jay Graf
Venture Partner @ New Enterprise Associates
Menlo Park, United States
Jay Graf is a Series B investor at New Enterprise Associates in Menlo Park focused on Health Care and Medical Device. Jay Graf joined NEA in October 2005 as a Venture Partner focusing primarily on medical device investments. Jay comes to NEA after nearly 30 years experience in the healthcare industry. He currently serves on the boards of American Medical Systems, Anulex Technologies, CVRx, Denali Medical, Ivantis, Rotation Medical and VytronUS. Mostrecently, Jay was Group Chairman of Guidant where he directed Guidant’s four operating groups before retiring in 2004. From 1992-2000, Jay was President of Guidant’s Cardiac Rhythm Management Group, now owned by Boston Scientific. Prior to that, he was Executive Vice President and COO of CPI from 1990 to 1992. Jay held a variety of management positions with Eli Lilly’s Pharmaceutical and Medical Device Division between 1976 and 1990. He is a graduate of Boston University with a Bachelor of Science degree in Business and Economics, and earned a Masters in Business Administration degree in finance from Indiana University. Jay served in the United States Air Force where he achieved the rank of Captain.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Jay Graf invests in
Stages Jay Graf invests in
Countries Jay Graf invests in
Investment Focus
Industry
- Health Care 5 (45%)
- Medical Device 5 (45%)
- Medical 3 (27%)
- Biotechnology 3 (27%)
- Health Diagnostics 2 (18%)
Stage
- Series B 2 (18%)
- Series C 1 (9%)
- Series E 1 (9%)
- Series F 1 (9%)
- Series G 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CVRx
|
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left andright carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota. | $50M / Private Equity / Jul 07, 2020 | |
|
CVRx
|
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left andright carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota. | $93M / Series G / Aug 09, 2019 | |
VytronUS
|
VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California. | $49M / Series C / Jul 29, 2016 | |
Ivantis
|
Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology. | $25M / Series B / Sep 23, 2014 | |
|
Ivantis
|
Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology. | $14M / Series B / Jan 13, 2014 | |
|
CVRx
|
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left andright carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota. | $29.6M / Series F / Jul 10, 2013 | |
|
Ivantis
|
Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology. | $27M / Series B / Jan 31, 2013 | |
Anulex Technologies
|
Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy). | $18.3M / Series E / Jun 07, 2010 | |
Rotation Medical
|
Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota. | $12M / Series B | |
|
Rotation Medical
|
Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota. | $27.2M / Series B | |
| See all 11 investments → | |||
Co-Investors
About New Enterprise Associates
New Enterprise Associates is a venture capital firm that invests in technology and healthcare startups. The firm engages with entrepreneurs at various stages of business development, providing support from initial funding to public offerings. The company focuses on the technology and healthcare industries.
New Enterprise Associates Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Sharata
Associate
|
|||
Anthony Florence
General Partner
|
|||
Bala Deshpande
Sr. Managing Director, India
|
|||
Hilarie Koplow-McAdams
Venture Partner
|
|||
|
Jay Graf
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jay Graf invest in?
Jay Graf invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Jay Graf last invest?
The most recent investment recorded for Jay Graf closed in Jul 2020. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
